5632-17-7

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloromethylquinoline is used as a key intermediate in the synthesis of various pharmaceutical compounds for its versatile chemical properties and reactivity, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Chloromethylquinoline serves as an intermediate in the production of agrochemicals, aiding in the development of effective pesticides and other agricultural chemicals to protect crops and enhance agricultural productivity.
Used in Organic Synthesis:
4-Chloromethylquinoline is utilized as a building block in organic synthesis, enabling the creation of a wide range of organic compounds for various applications, including the development of new materials and chemical products.
Used in Antitumor Research:
4-Chloromethylquinoline is studied for its potential antitumor activities, with ongoing research exploring its ability to target and inhibit the growth of cancer cells, offering a promising avenue for the development of novel anticancer therapies.
Used in Antimalarial Research:
4-Chloromethylquinoline is also being investigated for its antimalarial properties, with research focusing on its potential to combat malaria-causing parasites, contributing to the global effort to control and eradicate this infectious disease.

Upstream product

• 486-74-8 4-quinolinic acid 
• 4363-93-3 quinoline-4-carboxaldehyde 
• 63791-98-0 4-acetoxymethyl-quinolin-2-ol 
• 874499-04-4 acetic acid-(2-chloro-[4]quinolylmethyl ester) 
• 1205-74-9 4-bromo-3-oxo-N-phenylbutanamide 
• 432518-08-6 2-chloro-4-(hydroxymethyl)quinoline 
• 137354-54-2 4-(bromomethyl)-2-chloroquinoline 
• 4876-10-2 2-hydroxy-4-bromomethylquinoline 
• 634-47-9 2-chloro-4-methylquinoline 
• 6281-32-9 4-quinolylmethanol 
• 491-35-0 C₆H₄NCH₂CHCCH₂ 
• 7647-01-0 hydrogenchloride 
• 5632-16-6 4-(bromomethyl)quinoline 
• 4053-40-1 4-methylquinoline 1-oxide 

Downstream Products

• 1062368-21-1 4-quinolin-4-yl-2H-pyrazol-3-ylamine 
• 1062368-22-2 C₂₁H₁₃BrN₄ 
• 1062368-24-4 LDN-193189 
• 1062368-23-3 C₃₃H₂₈N₆O₂ 
• 1187313-01-4 C₂₆H₂₃N₅ 
• 1187313-00-3 C₂₇H₂₅N₅O 
• 1187313-20-7 C₃₁H₃₁N₅O₂ 
• 1187313-18-3 C₃₁H₂₉N₅O₂ 
• 1187313-23-0 C₃₁H₃₁N₅O₃ 
• 1187313-12-7 C₃₂H₃₃N₅O₃ 
• 1524735-13-4 2-(quinolin-4-ylmethoxy)benzaldehyde 
• 1043592-19-3 N-phenyl-5-(2-(quinolin-4-yl)methylthiophenyl)-1,3,4-oxadiazol-2-amine 
• 1043593-34-5 5-(2-(quinolin-4-yl)methoxyphenyl)-N-(3-trifluoromethylphenyl)-1,3,4-oxadiazol-2-amine 
• 14003-46-4 2-(quinolin-4-yl)acetonitrile 

Relevant academic research and scientific papers

THIAZOLE DERIVATIVES AS PROTEIN SECRETION INHIBITORS

Provided herein are secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same, wherein the compound has a structure of Formula (I), (II), or (III).

PYRIDAZINONES AND METHODS OF USE THEREOF

Disclosed are compounds according to Formula (A), and related tautomers and pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (A).

INHIBITORS OF THE BMP SIGNALING PATHWAY

The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.

Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors

A structure-activity relationship study of dorsomorphin, a previously identified inhibitor of SMAD 1/5/8 phosphorylation by bone morphogenetic protein (BMP) type 1 receptors ALK2, 3, and 6, revealed that increased inhibitory activity could be accomplished by replacing the pendent 4-pyridine ring with 4-quinoline. The activity contributions of various nitrogen atoms in the core pyrazolo[1,5-a]pyrimidine ring were also examined by preparing and evaluating pyrrolo[1,2-a]pyrimidine and pyrazolo[1,5-a]pyridine derivatives. In addition, increased mouse liver microsome stability was achieved by replacing the ether substituent on the pendent phenyl ring with piperazine. Finally, an optimized compound 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic characteristics (e.g., plasma t1/2 = 1.6 h) following intraperitoneal administration in mice. These studies provide useful molecular probes for examining the in vivo pharmacology of BMP signaling inhibition.

NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP

The present invention relates to a synthesis study of novel cyclic compounds having a quinolylalkylthio group represented by the formula (1), and pharmacological actions of the compounds. In the formula, the ring X represents: which may have halogen and/or alkyl; R1 and R2 independently represent hydrogen, alkyl, cycloalkyl, aryl or a (non) aromatic heterocycle; R3 represents qinolyl; A represents sulfur, sulfinyl or sulfonyl; and B represents alkylene.

NOVEL HETEROCYCLIC AMIDE DERIVATIVES HAVING DIHYDROOROTATE DEHYDROGENASE INHIBITING ACTIVITY

Novel heterocyclic amide derivatives having pharmacological effects, that is, compounds represented by the general formula (1) or salts thereof: (1) wherein X1-X2 is S-CH2 or the like; R1 is alkyl or the like; p is 0 to 7; R2 is hydrogen, alkyl, or the like; R3 is hydrogen, alkyl, or the like; Y1-Y2 is CH=CH or the like; R4 is halogeno, alkyl, or the like; q is 0 to 4; and R5 is halogeno, hydrogen, alkyl, or the like.

Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)

The present application describes novel bicyclic lactam derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein A, B, C, D, R1, and R2 are defined in the present specification, which are useful as metallo